This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (19)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Morton D. Grant, MD; Morton Coleman, MD

JAMA. 1975;231(6):623.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THE PROGNOSIS in acute lymphoblastic leukemia (ALL) has greatly improved because of effective chemotherapy, irradiation, or both for the prevention of central nervous system (CNS) leukemia. As prolonged remissions become more frequent, larger concern now focuses on the undesirable consequences of therapy.¹ Immunosuppression is the most serious problem, since this is thought to lead to the fatal nonbacterial infections seen increasingly during remissions.² Treatment may also potentiate the development of a second neoplasm, as shown in the following case report.

Report of a Case

In December 1972, a 17-year-old boy found to have acute lymphoblastic leukemia was admitted to St. Agnes Hospital. Hematological remission was obtained with vincristine sulfate, prednisone, and daunorubicin. He also received three courses of methotrexate intrathecally and craniospinal irradiation to a total of 1,800 R as prophylaxis against CNS leukemia. Therapy was maintained with mercaptopurine and methotrexate, with periodic reinforcement by the three drugs . . . [Full Text PDF of this Article]

Author Affiliations
From the Department of Medicine, St. Agnes Hospital, White Plains, NY (Dr. Grant), and the Division of Hematology, New York Hospital-Cornell Medical Center, New York (Dr. Coleman).

Footnotes
Reprint requests to 124 Park Avenue, Yonkers, NY 10703 (Dr. Grant).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?